A preprint paper, posted on MedRxiv, reports on meplazumab, a humanized anti-CD147 antibody, as and add-on therapy in patients with COVID-19 pneumonia in China.
Prof Ian Jones, Professor of Virology, University of Reading, said:
“The use of the antibody Meplazumab for Covid-19 seems very positive. It targets both the virus and the damage done by it during infection. The recovery rate of a range of patients improved significantly when Meplazumab was used. However, this is not a simple tablet treatment, it requires infusion while in hospital and drugs like this are not usually widely available, at least not in quantity. But it offers a potential therapy for severe cases which would improve recovery rates and free up beds faster. It clearly needs to be considered alongside other emerging treatments.”
All our previous output on this subject can be seen at this weblink: